Quince Therapeutics, Inc. (NASDAQ:QNCX – Get Free Report) Director David Lamond acquired 24,766 shares of Quince Therapeutics stock in a transaction on Thursday, August 17th. The stock was purchased at an average price of $1.29 per share, with a total value of $31,948.14. Following the transaction, the director now directly owns 2,097,109 shares in the […]
Quince Therapeutics, Inc. (NASDAQ:QNCX – Get Free Report) Director David Lamond purchased 24,766 shares of Quince Therapeutics stock in a transaction that occurred on Thursday, August 17th. The shares were bought at an average cost of $1.29 per share, for a total transaction of $31,948.14. Following the completion of the transaction, the director now directly […]
Quince Therapeutics, Inc. (NASDAQ:QNCX – Get Free Report) CEO Dirk Thye purchased 80,000 shares of the stock in a transaction dated Tuesday, August 8th. The stock was bought at an average cost of $1.24 per share, with a total value of $99,200.00. Following the completion of the purchase, the chief executive officer now owns 360,911 […]
An Important and Overlooked Cause of Alzheimer s theepochtimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theepochtimes.com Daily Mail and Mail on Sunday newspapers.
Cortexyme, Inc. (NASDAQ:CRTX – Free Report)’s stock price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.21 and traded as high as $1.49. Cortexyme shares last traded at $1.47, with a volume of 53,015 shares changing hands. Cortexyme Stock Down 1.4 % The firm […]